Heterologous expression and kinetic characterization of human cytochromes p-450: Validation of a pharmaceutical tool for drug metabolism research

Drug Metabolism and Disposition

Volumn 27, Issue 10, 1999, Pages 1117-1122

  Masimirembwa, Collen M ^a   Otter, Charlotta ^a   Berg, Mikael ^a   Jönsson, Marie ^a   Leidvik, Brith ^a   Jonsson, Eva ^a   Johansson, Thore ^a   Bäckman, Assar ^a   Edlund, Anders ^a   Andersson, Tommy B ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DICLOFENAC; ETHOXYRESORUFIN; FLAVONE DERIVATIVE; KETOCONAZOLE; MEPHENYTOIN; PACLITAXEL; QUERCETIN; QUINIDINE; SULFAPHENAZOLE; TESTOSTERONE;

ARTICLE; CATALYSIS; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SPECIFICITY; LIVER MICROSOME; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE;

EID: 0032874278     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
2. Boobis AR, McKillop D, Robinson DT, Adams DA and McCormick DJ (1998) Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica 28:493-506.
3. Boobis AR, Sesardic D, Murray BP, Edwards RJ, Singleton AM, Rich KJ, Murray S, Torre RDL, Segura J, Pelkonen O, Pasanen M, Kobayashi S, Zhi-Guang T and Davies DS (1990) Species variation in the response of the cytochrome P450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica 20:1139-1161.
4. Burke MD and Mayer RT (1985) Differential effects of phenobarbitone and 3-methylcholantrene induction of the hepatic microsomal metabolism and cytochrome P450-binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). Chem Biol Interact 45:243-258.
5. m. Br J Clin Pharmacol 45:503P-523P.
6. Crespi CL (1998) Effect of salt concentration on the activity of liver microsomal and cDNA expressed human cytochromes P450. International Symposium on Microsomes and Drug Oxidations, 20-24 July 1998 ALPHAVISA/ISMDO 98 Montpellier, France. Poster number 95.
7. Donahue SR, Flockhart DA, Abernethy DR and Ko JK (1997) Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther 62:572-577.
8. Friedberg T and Wolf CR (1996) Recombinant DNA technology as an investigative tool in drug metabolism research. Adv Drug Del Rev 22:187-213.
9. Frye RF, Matzke GR, Adedayo A, Porter JA and Branch RA (1997) Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolising enzymes. Clin Pharmacol Ther 62:365-376.
10. Gonzalez FP and Korzekwa KR (1995) Cytochromes P450 expression systems. Annu Rev Pharmacol Toxicol 35:369-390.
11. Gonzalez FP (1989) The molecular biology of cytochrome P450s. Pharmacol Rev 40:243-289.
12. Guengerich FP and Macdonald TL (1990) Mechanisms of cytochrome P450 catalysis. FASEB J 4:2453-2459.
13. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y and Sugiyama Y (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499.
14. Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A and Kamataki T (1998) High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol 55:1315-1325.
15. Kronbach T, Mathys D, Gut J, Catin T and Meyer UA (1987) High-performance liquid chromatography assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P450 isozymes of human liver. Anal Biochem 162:24-32.
16. Kudo S, Uchido M and Odomi M (1997) Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur J Clin Pharmacol 52:479-485.
17. Leemann T, Transon C and Dayer P (1993) Cytochrome P450 TD (CYP2C): A major monooxygenase catalysing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29-34.
18. Lin JH and Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403-449.
19. Mäenpää J, Hall SD, Ring BJ, Strom SC and Wrighton SA (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
20. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K and Nerbert DW (1993) The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12:1-51.
21. Omura T and Sato R (1964) Carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
22. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ and Tsutsui M (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681-693.
23. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T and Gonzalez FJ (1995) Chlorzoxazone is metabolised by human CYP1A2 as well as by CYP2E1. Pharmacogenetics 5:143-150.
24. Parkinson A (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24:45-57.
25. Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C and Parkinson A (1996) Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331:145-169.
26. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P4502E1. Chem Res Toxicol 3:566-573.
27. Prentis RA, Lis Y and Walker SR (1988) Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 25:387-396.
28. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ and Harris JW (1994) Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
29. Rendic S and Carlo FJD (1997) Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580.
30. Shet MS, Faulkner KM, Holmans PL, Fisher CW and Estabrook RW (1995) The effects of cytochrome b5, NADPH-P450 reductase, the lipid on the rate of 6β-hydroxylation of testosterone as catalysed by a human P450 3A4 fusion protein. Arch Biochem Biophys 318:334-321.
31. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-422.
32. Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M and Kobayashi S (1999) Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol 47:454-457.
33. Urban P, Cullin C and Pompon D (1990) Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells. Biochimie 72:463-472.
34. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP and Shimada T (1998) Comparative studies on the catalytic roles of cytochrome P450 2C9 and its cys- and leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 56:243-251.